Egypt has been telling the world it is a serious medical tourism destination for several years, and its healthcare authority has now put a number on that ambition. According to The Egyptian Gazette, Ahmed El-Sobky, chairman of the Egyptian Healthcare Authority, expects medical tourism revenues to rise by 76.7 per cent and to reach around $8 million for 2025. That figure is modest against the global medical tourism trade, and it is the direction rather than the absolute size that matters for a destination still building its reputation.
El-Sobky said the Authority treated 35,000 international patients over the previous year, and those patients travelled from 124 countries. The Egyptian Gazette reported that El-Sobky ties the growth to sustained upgrades across the Authority’s healthcare services and to a steady improvement in the quality of care delivered across its network of facilities.
Quality of Care as Egypt’s Medical Tourism Lever
Egypt’s spread of 124 source countries is the more interesting figure. A destination that draws 35,000 international patients from that many markets is not dependent on any single corridor, and that breadth is exactly the resilience that India is now missing after one regional conflict cut its Gulf inflow. Concentration is the quiet risk in medical tourism, and Egypt has so far avoided it.
The claim worth testing is the one about quality of care. El-Sobky attributes the revenue rise to service upgrades rather than to price, and that is the right emphasis for a maturing medical tourism destination. International patients choosing across borders weigh outcomes and safety alongside cost, and the destinations that last are the ones that can show accreditation, clinical results and continuity of care rather than a headline discount. A cheaper price wins the first cohort of medical tourists. Demonstrable quality of care wins the second, and the referrals that follow.
What 124 Countries Says About Egypt’s Reach
Five things move a patient across a border for treatment: better care, the best available care, cheaper care, faster care, or care that is simply unavailable at home. Egypt competes mostly on the cheaper and faster margins, with a growing case on quality, and the segments that travel well on those margins are dentistry, cosmetic procedures, geriatrics, orthopaedics and reproductive medicine. Dentistry and orthopaedics are the most price-elastic, and geriatrics rehabilitation travels well when a recovery stay is bundled into the price. None of that is stated in the Authority’s numbers, and the numbers would be far more persuasive if they were broken out by speciality, by orthopaedics and oncology outcomes, and by average length of stay rather than by revenue alone.
That 76.7 per cent rise reads well precisely because the base is small. Growth from a low base is easy to post and hard to sustain, and the real question for the Egyptian Healthcare Authority is what the figure looks like in three years, once the early cohort of medical tourists has been served and the destination has to compete on repeat business and reputation.
”In Egypt We Care” and the Branding Question
El-Sobky framed the ambition around a national brand, “In Egypt We Care”, and set the goal of establishing Egypt as a top-tier global medical tourism destination. A clear brand helps, and a reassuring one helps more in a market where trust is the scarce commodity. The risk is the familiar one for emerging destinations, which is that the brand runs ahead of the machinery it describes.
A slogan cannot substitute for the dull and decisive parts of a medical tourism destination, which are visa processing, airport transfers, interpreter cover, transparent pricing, medical-records continuity and a credible route to redress when a case goes wrong. Patients remember the machinery long after they forget the slogan. The destinations that convert a campaign into repeat international patients are the ones that fix the machinery first and market it second, and Egypt’s numbers will tell that story more honestly than its branding does.
Insurance Partnerships and Egypt’s Next Phase
El-Sobky said the next phase will concentrate on expanding partnerships with private insurance companies and brokers, with the aim of drawing a greater volume of international patients to Egypt. The logic is sound, because coverage and payment friction stop more patient travel than clinical doubt does, and an insurer that will pay for treatment in Egypt removes a real barrier for a patient weighing it against a domestic option.
The caution is equally real. Brokers and facilitators sell access and visibility, and the good ones sell trust, but the incentive in that layer is volume rather than outcome. Facilitators optimise for volume. A facilitator paid on commission has little reason to prefer the safest clinic over the one that pays the highest referral fee. Facilitators are also where a destination quietly loses margin, because a facilitator that owns the referral owns the patient. El-Sobky frames insurers as the lever, and insurers do remove real payment friction, yet insurers are not facilitators and should not be handed the clinical relationship. Egypt’s stronger play is to keep the clinical relationship close and to use insurers as a payment rail rather than as the front door to its medical tourism.
The trajectory is genuinely upward, and 35,000 international patients from 124 countries is a real base to build on. The task now is to convert a strong branding moment and a favourable growth rate into the durable machinery of a medical tourism destination, because the second 35,000 patients are harder to win than the first.
